Anthony C. Faber

7.5k citations

64 papers · 3.4k indexed · 1 hit paper · h-index 28

Molecular Biology top 5%
Oncology top 2%
Pulmonary and Respiratory Medicine top 2%
Cancer Research top 5%
Pathology and Forensic Medicine top 5%

Co-authors: Jeffrey A. Engelman Aaron N. Hata Youngchul Song Hiromichi Ebi Thomas C. Chiles Carlotta Costa Shizhen Emily Wang Maria G. Olivares
Topics: Cancer, Hypoxia, and Metabolism (10 papers)Lung Cancer Treatments and Mutations (9 papers)PI3K/AKT/mTOR signaling in cancer (7 papers)
Cited by: Oncology Cancer Research Molecular Biology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical Investigation The Journal of Experimental Medicine
Partner nations: United States Japan Jordan

In The Last Decade

Anthony C. Faber

62 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

2015 484 citations Aaron N. Hata, Jeffrey A. Engelman et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Anthony C. Faber

Since Specialization

Citations

This map shows the geographic impact of Anthony C. Faber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony C. Faber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony C. Faber more than expected).

Fields of papers citing papers by Anthony C. Faber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony C. Faber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony C. Faber. The network helps show where Anthony C. Faber may publish in the future.

Co-authorship network of co-authors of Anthony C. Faber

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony C. Faber. A scholar is included among the top collaborators of Anthony C. Faber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony C. Faber. Anthony C. Faber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment 2025 ·Cancer Research ·Tareq Saleh,Edward F. Greenberg,Anthony C. Faber,Hisashi Harada,David A. Gewirtz	2
2	The Innate Immune System and the TRAIL–Bcl-XL Axis Mediate a Sex Bias in Lung Cancer and Confer a Therapeutic Vulnerability in Females 2024 ·Cancer Research ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Chunqing Guo,(unknown),Xiaoyan Deng,Anthony C. Faber,(unknown),Dipankar Bandyopadhyay,Xiang‐Yang Wang,Alexander Neuwelt,Jennifer E. Koblinski,Paula D. Bos,Howard Li,Rebecca Martin,Joseph W. Landry	2
3	Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models 2022 ·PNAS Nexus ·Sheeba Jacob,(unknown),Jinyang Cai,Konstantinos V. Floros,(unknown),(unknown),(unknown),Mohammad A. Alzubi,Charles T. Jakubik,(unknown),Madhavi Puchalapalli,(unknown),Mikhail G. Dozmorov,Sosipatros A. Boikos,Bin Hu,J. Chuck Harrell,Cyril H. Benes,Jennifer E. Koblinski,Carlotta Costa,Anthony C. Faber	6
4	MYCN -Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis 2021 ·Cancer Research ·Konstantinos V. Floros,Jinyang Cai,Sheeba Jacob,Richard Kurupi,(unknown),(unknown),(unknown),Krista M. Powell,(unknown),Bin Hu,Madhavi Puchalapalli,Sivapriya Ramamoorthy,(unknown),Janina P. Lewis,Mikhail G. Dozmorov,John Glod,Jennifer E. Koblinski,Sosipatros A. Boikos,Anthony C. Faber	104
5	Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma 2021 ·Molecular Cancer Therapeutics ·Daniel A.R. Heisey,Sheeba Jacob,Timothy L. Lochmann,Richard Kurupi,(unknown),(unknown),(unknown),(unknown),Jennifer E. Koblinski,Mikhail G. Dozmorov,Sosipatros A. Boikos,Cyril H. Benes,Anthony C. Faber	11
6	Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma 2021 ·Molecular Cancer Therapeutics ·(unknown),Kateryna Krytska,Timothy L. Lochmann,Renata Sano,(unknown),(unknown),Qasim A. Khan,(unknown),(unknown),Jinyang Cai,Sheeba Jacob,Richard Kurupi,Bin Hu,Mikhail G. Dozmorov,Patricia Greninger,Andrew J. Souers,Cyril H. Benes,Yaël P. Mossé,Anthony C. Faber	13
7	The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity 2018 ·Clinical Cancer Research ·Daniel A.R. Heisey,Timothy L. Lochmann,Konstantinos V. Floros,(unknown),Krista M. Powell,Sheeba Jacob,(unknown),(unknown),Giovanna T. Stein,(unknown),Steven C. Smith,Cyril H. Benes,Joel Johansson,Andrew J. Souers,Sosipatros A. Boikos,Anthony C. Faber	22
8	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263 2018 ·Clinical Cancer Research ·Anahita Dastur,(unknown),Carlotta Costa,(unknown),August Williams,Joseph McClanaghan,Max Greenberg,Justine E. Roderick,Neha U. Patel,(unknown),Ultan McDermott,Mathew J. Garnett,Jorge A. Almenara,Steven Grant,Kathryn Rizzo,Jeffrey A. Engelman,Michelle A. Kelliher,Anthony C. Faber,Cyril H. Benes	16
9	An expanding role for osimertinib for the treatment of ErbB family driven NSCLC 2018 ·Translational Cancer Research ·Anthony C. Faber,Timothy F. Burns	1
10	One gene to rule them all…and in the darkness bind them 2018 ·Molecular & Cellular Oncology ·Konstantinos V. Floros,Anthony C. Faber	0
11	Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression 2017 ·Clinical Cancer Research ·Timothy L. Lochmann,Konstantinos V. Floros,Mitra Naseri,Krista M. Powell,(unknown),Ryan J. March,Giovanna T. Stein,Patricia Greninger,(unknown),Laura R. Saunders,Scott J. Dylla,Carlotta Costa,Sosipatros A. Boikos,Joel Johansson,Andrew J. Souers,Geoffrey W. Krystal,Hisashi Harada,Cyril H. Benes,Anthony C. Faber	93
12	Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS -Mutant Lung Cancer 2016 ·Cancer Discovery ·Hidenori Kitai,Hiromichi Ebi,Shuta Tomida,Konstantinos V. Floros,Hiroshi Kotani,Yuta Adachi,Satoshi Oizumi,Masaharu Nishimura,Anthony C. Faber,Seiji Yano	108
13	Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers 2014 ·Cancer Research ·Aaron N. Hata,Alan T. Yeo,Anthony C. Faber,Eugene Lifshits,Zhao Chen,Katherine A. Cheng,Zandra E. Walton,Kristopher A. Sarosiek,Anthony Letai,Rebecca S. Heist,Mari Mino–Kenudson,Kwok‐Kin Wong,Jeffrey A. Engelman	60
14	Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations 2014 ·Journal of Thoracic Oncology ·Hiromichi Ebi,Isao Oze,Takayuki Nakagawa,Hidemi Ito,Satoyo Hosono,Fumihiko Matsuda,Meiko Takahashi,Shinji Takeuchi,Yukinori Sakao,Toyoaki Hida,Anthony C. Faber,Hideo Tanaka,Yasushi Yatabe,Tetsuya Mitsudomi,Seiji Yano,Keitaro Matsuo	11
15	Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer 2013 ·Clinical Cancer Research ·Erin M. Coffee,Anthony C. Faber,Jatin Roper,Mark J. Sinnamon,Gautam Goel,(unknown),(unknown),Loredana Vecchione,Veerle de Vriendt,Barbara Weinstein,Roderick T. Bronson,Sabine Tejpar,Ramnik J. Xavier,Jeffrey A. Engelman,Eric S. Martin,Kenneth E. Hung	70
16	TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma 2013 ·Science Translational Medicine ·Ryan B. Corcoran,S. Michael Rothenberg,Aaron N. Hata,Anthony C. Faber,Adriano Piris,Rosalynn M. Nazarian,Ronald D. Brown,Jason T. Godfrey,Daniel Winokur,John R. Walsh,Mari Mino–Kenudson,Shyamala Maheswaran,Jeffrey Settleman,Jennifer A. Wargo,Keith T. Flaherty,Daniel A. Haber,Jeffrey A. Engelman	110
17	PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 2013 ·Proceedings of the National Academy of Sciences ·Hiromichi Ebi,Carlotta Costa,Anthony C. Faber,Madhuri Nishtala,Hiroshi Kotani,Dejan Juric,Patricia Della Pelle,Youngchul Song,Seiji Yano,Mari Mino–Kenudson,Cyril H. Benes,Jeffrey A. Engelman	174
18	Activation of PI3K Signaling in Merkel Cell Carcinoma 2012 ·Clinical Cancer Research ·Valentina Nardi,Youngchul Song,Juan A. Santamaria‐Barria,Arjola K. Cosper,Quynh Lam,Anthony C. Faber,Genevieve M. Boland,Beow Y. Yeap,Kristin Bergethon,(unknown),Hensin Tsao,Jeffrey Settleman,David P. Ryan,Darrell R. Borger,Atul K. Bhan,Mai P. Hoang,A. John Iafrate,James C. Cusack,Jeffrey A. Engelman,Dora Dias‐Santagata	87
19	An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation 2010 ·Cancer Research ·Birgit Schoeberl,Anthony C. Faber,Danan Li,Mei‐Chih Liang,Katherine Crosby,Matthew Onsum,Olga Burenkova,Emily Pace,Zandra E. Walton,Lin Nie,(unknown),Youngchul Song,Ulrik B. Nielsen,Jeffrey A. Engelman,Kwok‐Kin Wong	215
20	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins 2008 ·Journal of Clinical Investigation ·Marta Guix,Anthony C. Faber,Shizhen Emily Wang,Maria G. Olivares,Youngchul Song,(unknown),Cammie Rinehart,(unknown),Douglas Yee,Carlos L. Arteaga,Jeffrey A. Engelman	455

About Anthony C. Faber

Anthony C. Faber is a scholar working on Oncology, Cancer Research and Neurology, having authored 64 papers that have together received 3.4k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (10 papers), Lung Cancer Treatments and Mutations (9 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). The work is most often cited by research in Oncology (1.4k citations), Cancer Research (543 citations) and Molecular Biology (2.2k citations). Anthony C. Faber has collaborated with scholars based in United States, Japan and Jordan. Frequent co-authors include Jeffrey A. Engelman, Aaron N. Hata, Youngchul Song, Hiromichi Ebi, Thomas C. Chiles, Carlotta Costa, Shizhen Emily Wang, Maria G. Olivares, Carlos L. Arteaga and Marta Guix. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact